In GBM, miR155 has been shown to promote the secretion of pro-inflammatory cytokines such as IL-6 and TNF-α, the overexpression of iNOS (a M1 phenotype marker), and the reduction in CD206 (a M2 phenotype marker) levels (123). This evidence concerns the gene IL6 and glioblastoma.